Patient and healthcare professional acceptability of pharmacogenetic screening for DPYD and UGT1A1: A cross sectional survey

Preemptive pharmacogenetic testing to guide chemotherapy dosing in patients with gastrointestinal malignancies: a qualitative study of barriers to implementation

(2022) Kelsey S. Lau-Min et al.   BMC CANCER

Survey of US Medical Oncologists' Practices and Beliefs Regarding DPYD Testing Before Fluoropyrimidine Chemotherapy

(2022) Kyoin Koo et al.   JCO Oncology Practice

Pharmacogenomics guided dosing for fluoropyrimidine and irinotecan chemotherapies for patients with cancer (PACIFIC-PGx): study protocol of a multicentre clinical trial

(2022) Sarah Glewis et al.   ACTA ONCOLOGICA

Breast Medical Oncologists' Perspectives of Telemedicine for Breast Cancer Care: A Survey Study

(2022) Eleni Stavrou et al.   JCO Oncology Practice

Dutch pharmacogenetics working group (DPWG) guideline for the gene–drug interaction between UGT1A1 and irinotecan

(2022) Emma C. Hulshof et al.   EUROPEAN JOURNAL OF HUMAN GENETICS

DPD Testing Before Treatment With Fluoropyrimidines in the Amsterdam UMCs: An Evaluation of Current Pharmacogenetic Practice

(2020) Forike K. Martens et al.   Frontiers in Pharmacology

Teletrials: implementation of a new paradigm for clinical trials

(2020) Ian M Collins et al.   MEDICAL JOURNAL OF AUSTRALIA

Research Directions in the Clinical Implementation of Pharmacogenomics: An Overview of US Programs and Projects

(2018) Simona Volpi et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Enhancing Chemotherapy Capabilities in Rural Hospitals: Implementation of a Telechemotherapy Model (QReCS) in North Queensland, Australia

(2018) Sabe Sabesan et al.   Journal of Oncology Practice

Effectiveness and safety of reduced-dose fluoropyrimidine therapy in patients carrying the DPYD *2A variant: A matched pair analysis

(2018) Linda M. Henricks et al.   INTERNATIONAL JOURNAL OF CANCER

DPYD genotype-guided dose individualisation of fluoropyrimidine therapy in patients with cancer: a prospective safety analysis

(2018) Linda M Henricks et al.   LANCET ONCOLOGY

Patient experiences with pharmacogenetic testing in a primary care setting

(2016) Susanne B Haga et al.   PHARMACOGENOMICS